Left subclavian artery revascularization in zone 2 thoracic endovascular aortic repair is associated with lower stroke risk across all aortic diseases 
Left subclavian artery (LSA) coverage is required in as many as 40% of thoracic endovascular aortic repairs (TEVARs) for a wide variety of aortic diseases to achieve an adequate proximal seal. 1 However, the best management strategy for the LSA in zone 2 TEVAR deployment remains controversial, not only in the need for revascularization but also in the method of revascularization. Current Society for Vascular Surgery guidelines, published in 2010, recommend routine preoperative revascularization for nonemergent cases despite low-quality evidence. 2 Recent studies have suggested that revascularization of the LSA by debranching (bypass or transposition) is protective against stroke. 3 Zamor et al also found a link between coverage without revascularization and upper extremity ischemia. 4 In contrast, other studies have suggested that LSA coverage without revascularization during TEVAR does not increase stroke risk in a variety of aortic pathologic processes.
To further complicate the matter, multiple strategies for LSA revascularization exist, from endovascular in situ fenestration to parallel grafts to surgical debranching with either bypass or transposition. 8, 9 Our group has previously published our experience with laser fenestration and reported on the safety and efficacy of this technique in urgent and emergent TEVAR. 8, 10 An abundance of literature exists on the efficacy and durability of surgical revascularization of the LSA, but the technique is not without potential complications. These complications were recently described by Saouti et al to include transient nerve palsy and lymphatic leaks, and a meta-analysis of 51 studies by Rizvi et al noted a 4.4% rate of phrenic nerve injury as a result of primary revascularization. 11, 12 The aim of our study was twofold: to compare outcomes of zone 2 TEVAR deployment with and without LSA revascularization and to compare the outcomes of the different methods of LSA revascularization.
METHODS
A retrospective chart review was conducted using the electronic medical record (EMR) for Current Procedural Terminology (American Medical Association, Chicago, Ill) codes 33880, 33881, and 33889 to identify patients with all aortic diseases who underwent TEVAR from January 2007 to August 2014. Excluded were 143 patients with proximal landing zones 0, 1, 3, 4, or 5; patients with debranching or stenting of supra-aortic vessels other than the LSA; patients with previous or concomitant open ascending aortic repair; and patients with an aberrant right subclavian artery. The EMR review and waiver of consent were performed with approval of the Eastern Virginia Medical School Institutional Review Board and in compliance with the Health Insurance Portability and Accountability Act.
Patient information, including demographics, procedural data, and outcomes, was obtained from the EMR, deidentified, and collected in a password-protected Excel spreadsheet (Microsoft Corp, Redmond, Wash). Procedural intervention and stent graft landing zones were assigned from the operative report and confirmed with computed tomography or angiographic imaging when possible according to the classification set forth by Mitchel and Ishimaru. 13 Primary end points of the study included 30-day stroke and 30-day spinal cord injury (SCI). Secondary end points were 30-day procedure-related reintervention, freedom from aorta-related reintervention, aorta-related mortality, and all-cause mortality. All preoperative variables, including cohort characteristics and procedure indication, as well as procedure variables, including procedure type, characteristics, and timing, were studied to assess their impact on the primary and secondary end points. SPSS 22.0 software (IBM Corp, Armonk, NY) was used to perform statistical analysis. A c 2 analysis was used for univariate analysis of categorical variables, and a t-test or analysis of variance was used as appropriate for continuous variables. P < .05 was considered statistically significant. Multivariable analysis for each end point was completed using Cox regression analysis. Variables found to be significantly related to an end point on univariate analysis were included in multivariable analysis for that end point. If fewer than two variables were found to be significant on univariate analysis, the entrance P value for Cox regression analysis was increased to P < .2, and variables were included on the basis of a stepwise selection procedure. Kaplan-Meier survival analysis was used to evaluate freedom from aorta-related reintervention, aorta-related mortality, and all-cause mortality. A 2015 paper reported a 25% 30-day stroke rate in patients undergoing TEVAR without revascularization, which was reduced to 2% in patients who underwent revascularization. 4 Based on these reports, a priori calculations using a more conservative estimation that LSA revascularization would reduce stroke rates by about two-thirds (8%) resulted in a necessary sample size of 86 patients for a power of 80% at an a ¼ .05. We believed that this approximately two-thirds reduction in stroke rate was a clinically meaningful statistic. These estimates were also appropriate given preliminary internal records suggesting that roughly 100 patients during the 2007-2014 study period were likely to satisfy the inclusion criteria.
RESULTS
Demographics and procedure characteristics. A search of the EMR generated 305 patients with TEVAR, of whom 96 patients with zone 2 TEVAR deployments met our inclusion criteria. Demographic information is reported in Table I . The mean age of the patients was 62 years (range, 16.7-88.6 years; standard deviation, 15.9 years), with 61.5% male. Average body mass index of all patients in the cohort was 28.5 kg/m 2 . For the entire cohort, the rate of prior stroke was 12.5%, and the rate of previous aortic surgery was 11.5%; 80.2% of the cohort had a history of hypertension. Indications for TEVAR, described in Table II , included acute aortic dissection (n ¼ 25), chronic aortic dissection with aneurysmal degeneration (n ¼ 22), primary aortic aneurysms (n ¼ 21), penetrating aortic ulcers or intramural hematomas (n ¼ 17), and traumatic aortic injuries (n ¼ 11). In addition, 17 of the 96 patients also presented with aortic rupture secondary to the previously listed pathologic processes. Strategies for zone 2 TEVAR deployment included coverage of the LSA without revascularization (n ¼ 42) vs with revascularization (n ¼ 54), as reported in Table III . Patients who had unplanned revascularization performed after index TEVAR were considered primary coverage with aorta-related reinterventions. Methods of LSA revascularization included laser fenestration with stenting (n ¼ 33) and surgical revascularization: transposition (n ¼ 10) or bypass (n ¼ 11).
The only statistically significant differences of patients with LSA coverage without revascularization vs with revascularization were the rates of hypertension (29/42 [69.0%] Tables IV and V . Of the 54 patients who underwent LSA revascularization, 44 (81.5%) underwent LSA intervention at the time of TEVAR and 10 (18.5%) underwent LSA intervention at a mean time of 33 days before TEVAR (range, 4-63 days). A cerebrospinal fluid (CSF) drain was placed in 51 of 96 patients (53.1%), 48 preoperatively and 3 postoperatively. The average number of endografts placed per patient was 1.8. The average length of aortic coverage was 208.8 mm. Length of coverage was significantly longer in patients with LSA revascularization (229.6 6 82.9 mm) vs those without (181.5 6 74.5 mm; P ¼ .007). This difference reflects the practice at this institution to selectively revascularize patients with extended aortic coverage or previous aortic repair in addition to patients with a left internal mammary artery graft, occluded or atretic right vertebral artery, dominant left vertebral artery, posterior inferior cerebellar artery anomaly, and presence of a left arteriovenous fistula.
Outcomes. For the entire 96-patient cohort, the overall incidence of 30-day stroke was 7.3%; of 30-day SCI, 2.1%; and of 30-day procedure-related reintervention, 5.2%. At a mean follow-up of 24 months (range, 1-79 months), the rate of aorta-related reintervention was 15.6%, aortarelated mortality was 12.5%, and all-cause mortality was 29.2%. Outcome data are shown in Table VI .
Of the seven patients who suffered strokes within 30 days of the index operation, five (71.4%) were posterior circulation and two (28.6%) were multifocal; there were no anterior circulation strokes. Five were major strokes, two were minor, and all were embolic events (Table VII) . The 30-day stroke rate was statistically higher for LSA coverage without revascularization (6/ Multivariable analysis. Univariate analysis identified LSA coverage without revascularization (P ¼ .020) as the only factor to significantly affect the primary end point of 30-day stroke. Previous aortic surgery (P ¼ .14), maximum aortic diameter (P ¼ .15), current or former smoking status (P ¼ .17), and history of hypertension (P ¼ .17) were also included in multivariable analysis. Cox regression analysis (Table IX) For the end point of aorta-related mortality, univariate analysis identified preoperative visceral malperfusion (P ¼ .012), placement of a CSF drain (P ¼ .037), maximum diameter of the aorta (P ¼ .050), length of aorta covered by endograft (P ¼ .06), and history of hypertension (P ¼ .07) as factors affecting aorta-related mortality. Cox regression analysis showed that maximum aortic diameter was associated with aorta-related mortality (HR, 1.1; 95% CI, 1.01-1.14; P ¼ .011).
Univariate analysis revealed all-cause mortality to be related to intraoperative urinary output (P ¼ .010), aortic rupture (P ¼ .017), intraoperative intravenous fluid intake (P ¼ .033), and maximum aortic diameter (P ¼ .041). On multivariable analysis of these factors, maximum aortic diameter (HR, 1.0; 95% CI, 1.01-1.06; P ¼ .007) and rupture (HR, 3.1; 95% CI, 1.1-8.4; P ¼ .026) were found to be independently related to all-cause mortality.
For the end point of 30-day procedure-related reintervention, univariate analysis identified revascularization by subclavian-carotid transposition (P < .001), primary Further analysis was completed on the subgroup of patients who did not suffer traumatic aortic injury (n ¼ 85). Running a Cox regression on this smaller cohort for the end point of stroke using the previously established variables (LSA coverage without revascularization, maximum aortic diameter, previous aortic surgery, history of hypertension, and current or former smoker) showed that LSA coverage without revascularization is still associated with a higher rate of stroke (HR, 17.6; 95% CI, 1.4-223.7; P ¼ .027). Repeating this procedure for the remaining end points, we found no changes (ie, nothing becomes significant that previously was not, and vice versa), except for all-cause mortality, with which maximum aortic diameter is no longer associated.
Kaplan-Meier analysis. Kaplan-Meier analyses of survival free from aorta-related reintervention, aorta-related mortality, and all-cause mortality were completed. Kaplan-Meier analysis at 1 year revealed rates of survival free from aorta-related reintervention (Fig 1) , from aortarelated mortality (Fig 2) , and from all-cause mortality (Fig 3) of 88%, 88%, and 73%, respectively, for patients with LSA coverage without revascularization vs 86% (P ¼ .40), 91% (P ¼ .72), and 85% (P ¼ .54), respectively, for any form of LSA revascularization.
DISCUSSION
Multiple strategies exist for management of the LSA in diseases of the aorta requiring zone 2 TEVAR. Whether revascularization is protective against deleterious neurologic outcomes such as stroke and SCI is debatable, and series have been published on both sides of the issue. [3] [4] [5] [6] [7] Furthermore, there are multiple methods of revascularization. We focused our study on a comparison of LSA coverage without or with revascularization by carotidsubclavian bypass, subclavian-carotid transposition, or in situ laser fenestration.
This cohort of 96 patients is comparable in size to cohorts of other single-center studies, including a study by Contrella et al of 98 patients with LSA coverage for a variety of aortic diseases, 54 of whom underwent LSA revascularization by carotid-subclavian bypass.
14 A single-center study by Woo et al identified 70 patients with all aortic diseases with LSA coverage, 42 of whom underwent surgical revascularization by subclaviancarotid transposition or carotid-subclavian bypass. 15 The cohort of Lee et al consisted of 145 patients, more than this cohort, but only 32 of these patients underwent revascularization, significantly fewer than at this institution, and all by carotid-subclavian bypass. 16 None of these studies included patients with in situ laser fenestration as a method of LSA revascularization. Complication rates in this cohort are comparable to those in other studies of LSA management in TEVAR. Chung et al reported a stroke rate of 8.6% among patients with LSA coverage with aortic dissections or aneurysms, similar to a stroke rate of 7.3% in this cohort. 17 A similar stroke rate of 9.2% was reported by Contrella et al among 54 patients with aneurysms, dissections, pseudoaneurysms, traumatic tears, and penetrating ulcers who underwent LSA coverage without revascularization.
14 A recent meta-analysis by Waterford et al reported an overall stroke rate of 4.8% in 27 series with a variety of aortic diseases in a total of 1237 patients, which was further delineated as a stroke rate of 5.6% after LSA coverage without revascularization vs 3.1% with revascularization by bypass or transposition. 18 It is logical that LSA revascularization should be protective against ischemic stroke by maintaining maximal cerebral perfusion, as others have explained 2 ; however, the mechanism of protection against embolic strokes is less clear. We theorize that LSA revascularization is protective against embolic stroke because with surgical debranching, the LSA is removed as a source of possible emboli during TEVAR. Likewise, with laser fenestration, the proximal edge of the thoracic aortic endograft is landed directly at the level of the left common carotid artery, thereby reducing the amount of manipulation around the orifice of the LSA and decreasing the likelihood of dislodging a potential embolus. Likewise, the 4.9% rate of SCI with LSA coverage without revascularization in this cohort is comparable to a rate of 5.0% found by Zamor et al, whose cohort included patients with aneurysms, dissections, and traumatic aortic injuries. 4 Contrella et al reported a lower SCI rate of 2%, although this may be due to routine use of lumbar drains. 14 In our cohort, CSF There is limited research on in situ laser fenestration, and this sample size of 33 patients with laser fenestration is the largest in the literature. In contrast, previous studies from our institution reported by Ahanchi et al and Redlinger et al consisted of only 6 and 22 patients, respectively. 8, 10 Interestingly, compared with the in situ laser fenestration group, we found an increased rate of procedure-related reintervention in the surgical revascularization group; there were three access-related complications among the surgical revascularization group, whereas there were no procedure-related complications requiring reintervention among the laser fenestration group. In addition, compared with surgical revascularization by either bypass or transposition, laser fenestration did not increase rates of stroke, aortarelated reintervention, or all-cause mortality. These findings support previous assertions that laser fenestration is safe and feasible. 8, 10 Recently, a study of laser fenestration of Dacron grafts placed in seven pigs concluded that in situ fenestrations do not cause visible emboli, corroborating the safety of the technique. 19 This study is limited by the fact that it is retrospective and by the relatively small sample size of 96 patients. The small number of events may limit the ability of this study to detect a clinically important difference between treatment groups. In addition, given the limited sample size, we were unable to adequately adjust for confounding, and it is possible the results may be confounded. The retrospective nature of the study also introduces potential bias inherent in selective revascularization, in addition to preference of the surgeon and popularity of the procedure over time. For example, the technique of in situ laser fenestration came to prominence only in the last decade, whereas carotid-subclavian bypasses and subclavian-carotid transpositions are techniques that have been in use much longer. 10, 20 Because of the retrospective study design, we were also unable to standardize the method of stroke screening. We relied on physician notes corroborated with computed tomography imaging to determine whether a given patient experienced a stroke. Patients lost to follow-up represent another limitation, with 12 of the 96 patients in this study who were not otherwise known to be deceased having no documentation in the EMR within 2 years of this study. In addition, the heterogeneous nature of the study cohort in terms of aortic diseases could be considered a limitation, although our findings suggest that aortic disease was not associated with any outcome. For future studies, lengthier follow-up is needed to establish the long-term viability of the technique of in situ laser fenestration compared with surgical revascularization. A larger sample size to exclusively compare methods of LSA revascularization could also be used to corroborate these results. Furthermore, studies may seek to isolate one type of aortic disease and to examine the outcomes of different methods of LSA revascularization and so remove that as a confounding factor.
CONCLUSIONS
This retrospective, single-center experience shows that LSA coverage without revascularization is associated with an increased rate of 30-day stroke vs with revascularization by any method. In addition, the relationship between 30-day SCI and a lack of LSA revascularization approached significance, suggesting that coverage without revascularization may also increase the risk of SCI. The remaining primary end points, aorta-related reintervention, aorta-related mortality, and all-cause mortality, were similar between LSA coverage with and without revascularization. The different methods of LSA revascularization appear comparable with the exception of a possibly higher rate of 30-day procedure-related reintervention with surgical revascularization compared with laser fenestration. Last, urgency of TEVAR does not appear to affect rates of stroke or SCI. All forms of LSA revascularization, whether emergent/urgent or elective, synchronous or metachronous with TEVAR, provided similar and improved neurologic outcomes compared with coverage without revascularization. 
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